Claims
- 1. A compound selected from those formula (I): ##STR27## in which: A represents oxygen,
- X represents a single bond,
- R represents:
- hydrogen or lower alkyl, and in this case p=1 and B represents --CH.sub.2 --CH.sub.2 --NR.sub.1 --CO--R.sub.2 where R.sub.1 represents hydrogen or linear or branched lower alkyl, and
- R.sub.2 represents:
- hydrogen or,
- a cycloalkyl or linear branched lower alkyl, optionally substituted with halogen or,
- cycloalkyl substituted with linear or branched lower alkyl or,
- phenyl or indolyl or phenyl (lower alkyl) or substituted phenyl or substituted indolyl or substituted phenyl (lower alkyl), or
- a group of the formula: ##STR28## G representing linear or branched lower alkyl, R.sub.3 and R.sub.4, which may be identical or different, each represent lower alkyl or hydrogen or phenyl or phenyl (lower alkyl), or R.sub.3 and R.sub.4, together with the nitrogen atom to which they are attached, form a pyrrolidino group optionally substituted with one or more lower alkyl, or oxo, phenyl phenyl (lower alkyl), substituted phenyl or, substituted phenyl (lower alkyl), in the definitions of R.sub.2, R.sub.3 and R.sub.4, the term "substituted" qualifying phenyl and phenyl (lower alkyl) and indoyl meaning that these groups are substituted with one or more radicals chosen from lower alkyl, lower alkoxy, trifluoromethyl, and halogen, or alternatively R.sub.1, with R.sub.2 and the group N-Co, forms a pyrrolidinone system of formula: ##STR29## J being lower-alkylene having three carbon atoms, or R represents (CH.sub.2).sub.2 --NR.sub.1 --CO--R.sub.2 with R.sub.1 and R.sub.2 having the same definition as given above, and in which case p equals 0 or 1 and B represents lower alkoxy, and its isomers, epimers and diastereoisomers as well as, its addition salts with a pharmaceutically-acceptable acid or base, lower alkyl and lower alkoxy having 1 to 6 carbon atoms inclusive and cycloalkyl having 3 to 8 carbon atoms inclusive.
- 2. A compound as claimed in claim 1 in which R represents (CH.sub.2).sub.2 --NR.sub.1 --CO--R.sub.2, B represents methoxy, and p represents 1, its isomers as well as, where appropriate, its addition salts with a pharmaceutically-acceptable acid.
- 3. A compound as claimed in claim 1 in which R represents (CH.sub.2).sub.2 NHCOR.sub.2 wherein R.sub.2 represents C.sub.3 -C.sub.8 cycloalkyl or lower alkyl, B represents methoxy, and p equals 1.
- 4. A compound as claimed in claim 1 in which B represents (CH.sub.2).sub.2 NHCOR.sub.2 wherein R.sub.2 represents C.sub.3 -C.sub.8 cycloalkyl or C.sub.1 -C.sub.6 lower alkyl, as well as, where appropriate, its addition salts with a pharmaceutically-acceptable base.
- 5. A compound as claimed in claim 1 which is N-[2-(6-methoxy-3-benzoxazolinonyl)ethyl]acetamide.
- 6. A compound as claimed in claim 1 which is N-[2-(5-methoxy-3-benzoxazolinonyl)ethyl]acetamide.
- 7. A compound as claimed in claim 1 in which R represents CH.sub.2 --CH.sub.2 NHCO--CH.sub.3, B represents OCH.sub.3, and p equals 1.
- 8. A compound as claimed in claim 1 in which R represents hydrogen or methyl and B represents (CH.sub.2).sub.2 NHCOR.sub.2 wherein R.sub.2 represents C.sub.2 -C.sub.8 cycloalkyl or C.sub.1 -C.sub.6 lower alkyl, as well as, where appropriate, its addition salts with a pharmaceutically-acceptable base.
- 9. A compound as claimed in claim 1 which is N-[2-(3-methyl-6-benzoxazolinonyl)ethyl]acetamide.
- 10. A compound as claimed in claim 1 which is N-[2-(5-methoxy-3-benzoxazolinonyl)ethyl]cyclopropane carboxamide.
- 11. A compound as claimed in claim 1 which is N-[2-(5-methoxy-3-benzoxazolinonyl)ethyl]isobutyramide.
- 12. A compound as claimed in claim 1 which is N-[2-(6-methoxy-3-benzoxazolinonyl)ethyl]isobutyramide.
- 13. A compound as claimed in claim 1 which is N-[2-(6-benzoxazolinonyl)ethyl]acetamide.
- 14. A pharmaceutical composition containing as active principle a compound as claimed in claim 1, in combination with a pharmaceutically acceptable excipient or vehicle.
- 15. A method for treating a living animal afflicted with a sleep disorder, comprising the step of administering to the said living animal an amount of a compound of claim 1 which is effective for alleviation of the said condition.
Priority Claims (1)
Number |
Date |
Country |
Kind |
91 03538 |
Mar 1991 |
FRX |
|
Parent Case Info
The present application is a division of our prior-filed copending application Ser. No. 07/848,373, filed Mar. 9, 1992, now U.S. Pat. No. 5,240,919, issued Aug. 31, 1993.
US Referenced Citations (15)
Foreign Referenced Citations (1)
Number |
Date |
Country |
2667068 |
Mar 1992 |
FRX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
848373 |
Mar 1992 |
|